Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual piribedil dose-ranging crossover study in advanced Parkinson's disease with end-of-dose fluctuations
2005-000314-12Phase 2Completed
- Sponsor
- Servier
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of piribedil in Parkinson's disease (PD) (3 arms), sponsored by Servier. Primary endpoint: Effect on end-of-dose fluctuations after 14 days. Started Sep 2005; status: completed.
02
Drugs
piribedil
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2005-000314-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000314-12.